Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Topline Readout Expected in Q3 2026-

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its global LUMUS Phase 2b trial of ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for the treatment of systemic lupus erythematosus (SLE), the most common form of lupus.

“Completion of enrollment in our global LUMUS Phase 2b trial for SLE marks a significant milestone for Alumis, and importantly, for the lupus community,” said Martin Babler, President and Chief Executive Officer of Alumis. “This achievement reflects the dedication of our clinical partners, investigators, patients, and the entire Alumis team, positioning us to share topline data in the third quarter of 2026.”

“People living with SLE face a heavy burden and few treatment options,” added Dr. Jörn Drappa, Alumis’ Chief Medical Officer. “ESK-001, our next-generation oral TYK2 inhibitor, is designed to change that—selectively targeting key inflammatory drivers like type 1 IFN to maximize inhibition while minimizing off-target binding and effects. Clinical data in our psoriasis program has demonstrated that ESK-001 achieved full, sustained target inhibition and was generally well tolerated, positioning it as a promising oral therapy with potential for biologic-like clinical responses.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release